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Renal cell carcinoma (RCC) is the most common kidney
malignancy and has a poor prognosis owing to its resistance
to chemotherapy. RCC cells overexpress the transcription
factor, PAX2, normally expressed in fetal kidney but
downregulated at birth. Since Pax2 suppresses apoptosis
during renal development, we reasoned that PAX2 may
confer resistance to cisplatin-induced apoptosis in RCC. Here,
we show that PAX2 confers resistance to cisplatin-induced
apoptosis in normal kidney cells and fetal kidney explants.
Human embryonic kidney 293 cells transfected with a PAX2
expression vector and exposed to cisplatin (40 lM) exhibited
45715% as much caspase-3 cleavage compared to control
cells. Conversely, murine collecting duct cells stably
transfected with PAX2 antisense cDNA had twofold increase
in cisplatin-induced apoptosis. Murine fetal (embryonic day
15) kidney explants from PAX21Neuþ / mice exposed to
cisplatin (25 lM24 h) had 50% increased apoptosis (terminal
deoxynucleotidyl transferase-mediated dUTP nick-end
labelling staining). We then show that RCC cells (CAKI-1
(human, Caucasian, kidney, carcinoma) and ACHN (human,
Caucasian, kidney, adenocarcinoma)) express PAX2 protein.
PAX2-small interfering RNA (100 nM) reduces endogenous
PAX2 protein (10% of baseline) and induces apoptosis
(Annexin-V staining). Pax2 knockdown sensitized RCC
cells to cisplatin-induced apoptosis, killing 50–60% of
cisplatin-resistant ACHN and CAKI-1 cells. These findings
suggest that PAX2 confers resistance to cisplatin-induced
apoptosis in non-transformed kidney cells and fetal kidney
explants. Similarly, Pax2 overexpression in RCC cells
contributes to cisplatin resistance. Conceivably, a therapeutic
strategy that inactivates Pax2 in vivo might enhance the
efficacy of conventional cytotoxic drugs against RCC.
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It is estimated that over 30 000 people in the United States
have renal cell carcinoma (RCC); over 10 000 RCC-related
deaths occur each year.1 Only 40% of patients have disease
confined to the kidney at the time of diagnosis and nearly
25% of patients present with symptoms of metastatic lesions.
With current therapy, the 1-year survival of patient with
metastatic RCC is less than 50%.2 This resistance of RCC to
conventional medical therapy remains the primary obstacle
to survival and makes the development of new therapeutic
strategies imperative.
Cisplatin is among the most widely used and most
effective chemotherapeutic agents for many types of human
cancer. Cisplatin is thought to act through direct binding to
DNA causing cisplatin–DNA adducts. If cisplatin–DNA
adducts are not efficiently processed by the cellular repair
mechanism, the pathway of programmed cell death is
initiated.3 Molecular mechanisms, which subvert these
proapoptotic signals, are thought to account for resistance
of tumours to chemotherapy.4,5
In some malignancies, resistance to apoptosis has been
attributed to overexpression of genes encoding endogenous
inhibitors of apoptosis,6–8 but the specific cause for the high
resistance of RCC to therapy is unknown.
During normal kidney development, the transcription
factor, PAX2, is expressed both in the ureteric bud and
mesenchymal cell lineages. We have recently shown that PAX2
functions to suppress programmed cell death during
nephrogenesis; PAX2 gene mutations cause increased apop-
tosis of ureteric bud cells with resultant renal hypoplasia.9–12
Once nephrogenesis is complete, however, renal PAX2
expression is rapidly downregulated and is barely detectable
in the mature kidney. On the other hand, PAX2 is
inappropriately re-expressed in a variety of cancers – parti-
cularly in RCC.13–15 Thus, the powerful antiapoptotic function
of PAX2 might contribute to the resistance of RCC cells to
chemotherapy. If so, inhibitors of PAX2 expression might
enhance programmed cell death in RCC, enhancing the
efficacy of chemotherapeutic agents such as cisplatin.
In this report, we demonstrate that transfection of PAX2
cDNA into a human embryonic kidney 293 (HEK293) cell
line confers resistance to cisplatin-induced apoptosis. Con-
versely, we show that inhibition of PAX2 using antisense
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cDNA enhances cisplatin-induced apoptosis of a murine
collecting duct cell (IMCD) and that cisplatin-induced
apoptosis is increased in fetal kidney explants from hetero-
zygous PAX21Neu mutant mice. Similarly, we show that small
interfering RNAs (siRNA) can be used to inhibit PAX2
expression in two RCC cell lines (ACHN (human, Caucasian,
kidney, adenocarcinoma) and CAKI-1 (human, Caucasian,
kidney, carcinoma)) derived from clear-cell carcinomas and
that PAX2-siRNA enhances apoptosis and cell death of
cisplatin-resistant RCC cells.
RESULTS
PAX2 confers resistant to cisplatin-induced apoptosis in
non-transformed kidney cells
To evaluate whether PAX2 inhibits cisplatin-induced apop-
tosis in HEK cells, we stably transfected the HEK293 cell line
with an expression vector containing full-length human
PAX2b cDNA (or empty vector as control). Endogenous
PAX2 protein was not detectable in HEK293 cells transfected
with the empty expression vector or in the parental HEK293
cell line. However, as shown in Figure 1a, PAX2 protein was
highly expressed in the HEK293/PAX2 transfectants, provid-
ing an opportunity to examine the effects of aberrant Pax2
overexpression on cell survival.
HEK293/PAX2 and control HEK293 cells were exposed to
cisplatin (40 mM) and assayed for the activation of caspase-3
at 24 h. HEK293/PAX2 cells exhibited only 45% as much
caspase-3 activation as controls in response to cisplatin
(Figure 1b).
Reduced endogenous PAX2 expression increases
susceptibility to cisplatin-induced apoptosis in renal
collecting duct cells
To examine the effect of PAX2 inactivation on susceptibility
to apoptosis, we utilized a cell line (IMCD) derived from
murine renal collecting duct. IMCD cells were chosen
because the collecting duct lineage is known to express high
levels of endogenous PAX2 protein (Figure 2a). IMCD cells
were stably transfected with a cytomegalovirus-driven
expression vector containing a full-length antisense hPAX2b
cDNA. Stable transfectants (IMCD/PAX2-AS) showed sig-
nificant reduction of PAX2 protein levels (30% of controls)
(Figure 2a). These cells were cultured in the presence or
absence of 40 mM cisplatin and assayed for caspase-3
activation after 24 h. In preliminary dose–response studies,
we found that caspase-3 activation (cleavage) at 24 h climbs
with increasing cisplatin concentration, peaks at 40 mM and
then falls off at higher concentrations as cell necrosis ensues
(data not shown). In the absence of cisplatin, low basal levels
of apoptosis were equivalent in IMCD/PAX2-AS and control
IMCD cells. However, in the presence of cisplatin (40 mM),
activation (cleavage) of caspase-3 was twofold higher in
IMCD/PAX2-AS transfectants compared to control IMCD
cells (Figure 2b).
Reduced PAX2 expression in heterozygous mutant (PAX21Neu)
mice increases susceptibility of fetal kidney explants to
cisplatin
To demonstrate that genetically reduced PAX2 expression
increases apoptosis induced by cisplatin, whole fetal kidneys
(embryonic day 15 (E15)) were isolated from wild-type and
heterozygous mutant PAX21Neu mice and placed in explant
culture as described previously.12 Following exposure to
cisplatin (25 mM) for 24 h, explants were processed for
terminal deoxynucleotidyl transferase-mediated dUTP nick-
end labeling (TUNEL) immunohistochemistry. Untreated
apoptosis in wild-type explants was only slightly lower than
E15 PAX21Neu kidney explants (Figure 3). However, in the
presence of cisplatin, the intensity of TUNEL staining per
unit cross-sectional area was increased ninefold above the
untreated baseline in mutant explants compared to an
increase above baseline of only fivefold in wild-type explants
(Po0.01, mutant vs wild type) (Figure 3).
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Figure 1 | PAX2 expression confers resistance to cisplatin-induced
apoptosis. (a) HEK293 lacking endogenous PAX2 were stably
transfected with hPAX2 cDNA to generate the HEK293/PAX2 cell line
with elevated PAX2 protein expression. (b) HEK293 control and
HEK293/PAX2 cell lines were exposed to cisplatin (40 mM) and
assessed for caspase-3 activation (cleavage) at 24 h. Bar graphs
represent the mean and s.d. of three experiments (each experiment
was performed in triplicate); HEK293/PAX2 vs HEK293 control,
*Po0.01.
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Figure 2 | Reduced PAX2 expression sensitizes IMCD cells to
cisplatin. IMCD cells were stably transfected with a vector containing
a full-length antisense hPAX2b cDNA. (a) Stable transfectants (IMCD/
PAX2-AS) (third lane) had reduced levels of PAX2 protein compared
to untransfected IMCD cells (first lane) or IMCD/empty vector cells
(second lane) by Western immunoblotting. The cells were treated
with cisplatin (40 mM). (b) The sensitivity to cisplatin-induced
apoptosis was assessed by assay of caspase-3 activation (cleavage) at
24 h. The bar graph represents the mean and s.d. of three
experiments (each experiment was performed in triplicate); IMCD/
PAX2-AS vs IMCD control, *Po0.01.
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siRNA inactivation of endogenous PAX2 induces apoptosis in
RCC cells
To demonstrate endogenous PAX2 expression in RCC cells,
we assessed the 43-kDa PAX2 protein band intensity on
Western immunoblots of ACHN and CAKI-1 cell lines
derived from human clear-cell carcinomas. Both cell lines
exhibited high levels of endogenous PAX2 protein (Figure 4a
and b).
In order to inhibit endogenous PAX2 protein expression,
the cells were exposed to a pool of four PAX2-siRNAs (25 nM
each) for 24 or 48 h. PAX2 protein levels fell progressively
with increased exposure time and by 48 h were nearly
undetectable in CAKI-1 cells and reduced to 15% of baseline
in ACHN cells. (Figure 4a and b)
To assess whether PAX2 suppression induces apoptosis in
RCC cells, ACHN and CAKI-1 cells were exposed to 100 nM
siRNAs or control medium for 24 and 48 h. Cells undergoing
apoptosis were then detected by fluorescent Annexin-V
staining in situ 24 and 48 h post-transfection (Figures 5 and
6). For CAKI-1 cells, exposure to PAX2-siRNAs resulted in
20.5 and 38.6% Annexin (þ ) cells after 48 h compared to
6.8% Annexin (þ ) cells exposed to nonspecific control
siRNAs. Similarly, ACHN cells exposed to PAX2-siRNAs
showed 15 and 31.7% Annexin (þ ) cells at 24 and 48 h,
respectively, vs 5% Annexin (þ ) cells with nonspecific
control-siRNAs (Po0.001) (Figures 5 and 6). The effect of
PAX2-siRNAs was specific to cells expressing endogenous
PAX2 since the siRNAs had no effect on survival of HEK293
cells (data not shown).
Effect of PAX2-siRNA and cisplatin on RCC cell survival and
apoptosis is additive
We examined whether PAX2 inactivation might add to the
cell death caused by cisplatin exposure in vitro. CAKI-1 and
ACHN cells were treated with PAX2-siRNAs or control-
siRNAs for 24 h, followed by exposure to various doses of
cisplatin (10–160 mmol/l) for a further 24 h. The effect of
0
5
10
15
20
25
30
35
40
45
50
Cisplatin + − + −
%
 T
UN
EL
 s
ta
in
in
g/
cr
os
s-
se
ct
io
na
l s
ur
fa
ce
 a
re
a 
(m
m2
)
Mutant Wild typeMutant Wild type
*
Figure 3 | Genetic reduction of PAX2 increases susceptibility to
cisplatin-induced apoptosis. Whole fetal kidneys were microdis-
sected from E15Pax21Neu mutant (N¼ 18 kidneys) and wild-type
(N¼ 10 kidneys) mice and cultured at 371C for 30 h. Half of the
explants from each group were treated with cisplatin (25 mM) in the
culture medium for 24 h. Apoptosis was measured by TUNEL staining
and quantified using Northern Eclipse software (staining intensity per
mm2). Cisplatin caused a ninefold increase in apoptosis in the
Pax21Neu explants, but only a fivefold increase in wild-type explants
(*Po0.01).
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Figure 4 | Endogenous PAX2 protein expression by CAKI-1 and
ACHN renal carcinoma cells is suppressed by PAX2-siRNA.
Endogenous expression of 42 kDa PAX2 protein was confirmed by
Western immunoblotting for both (a) CAKI-1 and (b) ACHN RCC cell
lines from the NCI-60 panel. Cells were seeded at 105 cells/ml in
24-well plates and exposed to PAX2-siRNAs or control-siRNAs
(100 nM) added to media with Lipofectamine 2000 according to the
manufacturer’s protocol. PAX2 protein level was assessed by Western
immunoblotting after 24 and 48 h treatment.
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Figure 5 | Inhibition of PAX2 induces apoptosis of RCC cell lines.
CAKI-1 and ACHN cells were treated with 100 nM PAX2-siRNA or
control-siRNA (Dharmacon). Apoptosis was measured by counting
the percentage of cells that were Annexin-V (þ ) after 24 and 48 h.
The bar graph represents the mean and s.d. for three experiments
(each experiment was performed in triplicate); PAX2-siRNA vs
siRNA-control, *Po 0.01.
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combined treatment on cell viability was assessed at 48 h as
above and expressed as a percent of untreated cells.
Addition of PAX2-siRNAs to cisplatin-treated cells
significantly reduced survival of CAKI-1 cells compared
to control siRNA-treated cells: 62.2 vs 37% (cispla-
tin¼ 10 mmol/l); 42.21 vs 26.8% (cisplatin¼ 20 mmol/l);
25.2 vs 15.5% (cisplatin¼ 40 mmol/l), respectively (Figure 7).
Similarly, exposure of ACHN cells to PAX2-siRNAs killed
80 vs 42.8% (cisplatin¼ 10 mmol/l); 61.4 vs 34.7% (cispla-
tin¼ 20 mm/l) and 45 vs 22% (cisplatin¼ 40 mmol/l) of
cisplatin-resistant cells, respectively (Figure 7a and b).
The level of apoptosis of RCC cells in response to the
combined treatment was analysed by Annexin-V staining
in situ. Treatment with cisplatin (10–40 mM) plus PAX2-
siRNAs (25 nM each) resulted in a percentage of cells
undergoing apoptosis equivalent to the sum of the individual
treatments (Figure 7c and d). The percentage of Annexin
(þ ) cells increased in a linear manner with increasing
cisplatin dose up to 40 mmol/l. At higher doses, cell
detachment and increased propidium iodide staining of
dying necrotic cells were noted (data not shown).
Therapeutic cell death of the combined treatment with
PAX2-siRNA and cisplatin is caspases dependent
To demonstrate that the effects of PAX2-siRNA and cisplatin
on RCC cell survival are mediated by the caspase pathways of
programmed cell death, we analysed the effect of a broad
caspase (caspase-3, -5 and -7) inhibitor (Benzylcarbonyl-Val-
Ala-Asp (OMe) fluoromethyl ketone (Z-VAD-fmk)). The
combined cytotoxicity of cisplatin and PAX2-siRNAs was
490% inhibited by concurrent exposure to 25 mmol/l
Z-VAD-fmk (Figure 8).
DISCUSSION
We have recently shown that PAX2 suppresses apoptosis in
the ureteric bud lineage during nephrogenesis.10 By suppres-
sing programmed cell death, PAX2 facilitates efficient
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Figure 6 | Immunocytochemical staining for Annexin-V in PAX2-
siRNA-treated cells vs control-siRNA-treated cells after 24 h.
(a) ACHN and (b) CAKI-1 were stained with anti-Annexin-V
fluorescent (green) antibody, and with 40,6-diamidinophenylindole
(blue).
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Figure 7 | RCC cell death caused by PAX2-siRNA and cisplatin are
additive. The viability of (a, c) CAKI-1 and (b, d) ACHN cells was
assessed after 24 h of cisplatin exposure and 24 h pre-treatment with
PAX2-siRNAs or control-siRNAs. Cell survival was measured by
colorimetric assay of cellular dehydrogenase activity and expressed
as a percentage of that in untreated cells. PAX2-siRNA vs
siRNA-control, *Po0.01.
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Figure 8 | Combined killing induced by PAX2 inhibition plus
cisplatin is caspase dependent. CAKI-1 and ACHN cells were treated
with 25mM Z-VAD-fmk, a broad caspase inhibitor. After 4 h, PAX2-
siRNAs or control-siRNAs were added to the media. At 24 h, cells were
exposed to cisplatin 30 mmol/l. The effect of Z-VAD-fmk on the
combined cytotoxicity of cisplatin and PAX2-siRNAs was measured by
colorimetric assay of cellular dehydrogenase activity at 48 h. For each
cell line, PAX2-siRNA plus cisplatin significantly lowered cell survival
vs siRNA-control (*Po0.01), but cell survival was fully restored to
control levels in the presence of Z-VAD-fmk (**Po0.01).
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branching of the ureteric bud and optimizes the final
nephron number.9,12 However, once nephrogenesis is com-
plete, renal PAX2 expression is rapidly downregulated and is
barely detectable in mature kidney (Cohen JT et al. Pediatric
Academic Societies, Annual Meeting, San-Francisco CA, 2004;
abstract 3276). In a variety of cancers – particularly in RCCs –
there is inappropriate re-expression of PAX2.12,14,16 Since
PAX2 normally exerts a powerful antiapoptotic function
during development, we reasoned that it might have the same
(but undesirable) effect on renal carcinoma cells, contributing
to their relative resistance to chemotherapy (RCC).
Cisplatin has been used as an anticancer therapy for many
years and its cytotoxic mode of action is primarily mediated
by its interaction with DNA to form platinum–DNA
adducts.5 Cisplatin interaction with DNA induces several
signal transduction pathways, including those involving p53,
p73, caspases, cyclins, cyclin-dependent kinases, retinoblast-
oma protein, protein kinase C, mitogen-activated protein
kinase and phosphatidylinositol 30-kinase/Akt, and eventually
results in the activation of apoptosis.3 Possible mechanisms
of resistance to cisplatin include reduced intracellular
accumulation of cisplatin, enhanced drug inactivation and
increased repair activity of DNA damage. However, since
cisplatin cytotoxicity is mediated through the pathways
of programmed cell death, mechanisms that block these
pathways might also contribute to cisplatin resistance.3
While PAX2 clearly suppresses basal apoptosis in devel-
oping kidney, the molecular mechanism underlying this
phenomenon is not yet known. To determine whether the
developmental effects of PAX2 can be generalized to
cisplatin-induced apoptosis, we transfected HEK cells with
a PAX2 expression vector in the presence or absence of
cisplatin. PAX2 was as effective in suppressing apoptosis
associated with cisplatin exposure as it is in other settings.10
Similarly, we were able to show a protective effect of PAX2 on
cisplatin-induced apoptosis in normal murine fetal kidney
explants. Other investigators have reported that PAX2
enhances resistance of endothelial cells to vincristine-induced
apoptosis.17 Taken together, these observations suggest that
PAX2 influences core components of the programmed cell
death pathway in normal cells, independent of the proapop-
totic stimulus.
We identified significant levels of PAX2 protein in RCC
cell lines (CAKI-1 and ACHN). Initial efforts to inhibit PAX2
with antisense oligonucleotides were met with limited
success. However, we found that PAX2 RNA interference
powerfully inhibited PAX2 protein expression and signifi-
cantly increased basal apoptosis in RCC cells. Furthermore,
one-third of RCC cells resistant to cisplatin were killed by
exposure to the PAX2-siRNA. Our results extend previous
observations suggesting that PAX2 affects basal RCC cell
survival in vitro.16
Recently, direct infusion of siRNA into the tail vein of
mice selectively inhibited renal Fas protein and mRNA
expression and Fas-mediated apoptosis following ischaemic
injury to the kidney.18 Similarly, it has been shown that
injection of siRNA into the jugular vein could functionally
silence vasopressin V2 receptors in the mouse kidney.19 It is
conceivable, therefore, that a PAX2-siRNA could be delivered
successfully into the kidney in vivo. Although PAX2 function
is critical during embryogenesis, PAX2 levels fall to nearly
undetectable levels in normal adult kidney. Thus, PAX2
inhibition should preferentially affect cancer cell viability
with minimal or no effect on normal adult tissue.
RCC cells are relatively resistant to programmed cell
death, but the molecular mechanism is not well understood.
Recent studies indicate that neither B-cell lymphoma-2 nor
Bcl2-associated X protein-a (Bax-a) expression influence
progression of RCC. On the other hand, the level of an
endogenous caspase inhibitor, X-linked inhibitor of apopto-
sis, correlates with decreased patient survival of patients with
clear-cell carcinoma, suggesting a possible role for this family
of molecules.20–25 Interestingly, preliminary observations by
Dziarmaga et al. suggest that PAX2 may activate transcription
of another inhibitors of apoptosis, the neural apoptosis-
inhibitory protein (Dziarmaga A et al. Proceedings, Inter-
national Pediatric Nephrology Association Workshop, Adelaide,
2004, p 64), but the importance of neural apoptosis-
inhibitory protein in the regulation of renal cell apoptosis
has not been established.
PAX2 expression is aberrantly re-expressed in a variety of
cancers including prostate, breast, leukaemia and Wilms’
tumour.26–31 In adults, all major subtypes of RCC express
Pax2 and the level of PAX2 protein correlates with aggressive
tumour behaviour and increased proliferation index.3,15 This
observation suggests Pax2 could also serve as a prominent
tumour marker for patient with RCC and as a potential
candidate for targeted molecular therapy for a variety of
non-renal cancers.
For patients with RCC, an effective therapeutic strategy
remains elusive. The overall response rate of RCC patients to
current anticancer agents (including cisplatin) is only
10–20%.5 Our findings suggest that strategies to inactivate
aberrant PAX2 expression in tumour tissue might be used in
combination with standard anticancer drugs to enhance
therapy of RCC.
MATERIALS AND METHODS
Cell culture
The two human RCC cell lines (ACHN and CAKI-1 cells), selected
from the NCI-60 cancer cell panel, were obtained from the
American Type Culture Collection (Rockville, MD, USA) and
maintained as adherent monolayer cultures in Roswell Park
Memorial Institute culture medium (Life Technologies, Carlsbad
CA, USA), supplemented with 10% fetal bovine serum (Life
Technologies).
SiRNA inactivation of PAX2
RCC cells were transfected with a commercially available pool of
four double-stranded siRNAs targeting PAX2 (siPAX2smart pool
Dharmacon cat. no. M-003307-00-05), mRNA (Accession no.
NM_000278) or a pool of control siRNAs (siControl Dharmacon
cat. no. D-001206-13-20).
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All siRNAs were duplexed, desalted, 20 deprotected and purified
(480%) by Dharmacon Inc. (Dharmacon, CO). Cells were seeded
at 105 cells/ml in 24-well plates. PAX2-siRNAs or the control-
siRNAs (100 nM) were added to media using a lipophilic transfection
reagent according to the manufacturer’s protocol (Lipofectamine
2000, Invitrogen Inc., Carlsbad, CA, USA).
Western immunoblotting
A total of 30mg of protein extracted from each transfected cell
population was resolved on 10% sodium dodecyl sulphate-
polyacrylamide gels 100 V for 1.5 h at 41C, and then transferred
over 1 h at 100 V (41C) onto polyvinylidene difluoride membranes
(Bio-Rad, Mississauga, ON, Canada). Blots were probed with
polyclonal anti-PAX2 antibody (Zymed, San Francisco, CA, USA)
followed by anti-rabbit IgG secondary antibody and detected with
an enhanced chemiluminescence detection system (Amersham,
Piscataway, NJ, USA). Membranes probed for PAX2 were reprobed
for b-actin (Oncogene Research Products, San Diego, CA, USA) to
normalize for loading differences and to allow comparisons between
transfected and untransfected cell populations. Band intensities were
quantified using an image acquisition system (Imaging Research, St
Catharines, ON, Canada).
Stably transfected cell lines
HEK293/hPAX2 cells were stably co-transfected with a neomycin
resistance vector and a cytomegalovirus-driven expression plasmid
containing the full-length human PAX2b cDNA as described
previously.32 IMCD cells, derived from the IMCD lineage, were
co-transfected with a neomycin resistance vector and a cytomega-
lovirus-driven expression vector containing a full-length antisense
human PAX2b cDNA. Stably transfected clones were selected in
media containing neomycin.
Culture of whole fetal kidney explants
Kidneys were microdissected from wild-type and heterozygous
mutant PAX21Neu E15 embryos and cultured at 371C as described
previously.9,12 These mice express about half the normal amount of
PAX2 protein in fetal kidney.9,12At the end of the 30 h culture
period, explants were fixed in 4% formaldehyde for 1 h and then
transferred to 60% ethanol.
TUNEL staining
The in situ cell death detection POD kit (Roche Diagnostics, Laval,
QC, Canada) was used to detect apoptosis by TUNEL in serial
sagital sections of paraffin-embedded wild-type and PAX21Neu
mutant kidneys as described previously.12 TUNEL-stained sections
of fetal mouse kidney were examined by light microscopy and Spot
Advanced digital imaging software. The images obtained (magni-
fication  40) were analysed using Northern Eclipse software to
generate a value representing the percent of TUNEL (þ ) cells per
cross-sectional surface area (mm2) covered by a user-defined
threshold of TUNEL staining intensity. All quantification of apo-
ptosis was carried out blindly and without the knowledge of the
genotype or treatment status.
Caspase-3 assay
The caspase-3 substrate N-acetyl-Asp-Glu-Val-Asp-7-amino-4-tri-
fluoromethylcoumarin (BD Pharmingen San Jose, CA, USA) was
used in caspase-3 assays according to the manufacturer’s instruc-
tions. Cell lysate (100 mg) was added to the reaction buffer (20 mM
N-2-hydroxyethylpiperazine-N0-2-ethanesulphonic acid, pH 7.4,
100 mM sodium chloride, 10 mM dithiothreitol, 0.1% 3-[(3-chola-
mydopropyl)-dimethylammonio]-2-hydroxy-1-propanesulphonic
acid, 10% sucrose) containing 125 mM of N-acetyl-Asp-Glu-Val-Asp-
7-amino-4-trifluoromethylcoumarin in a 1 ml cuvette. Fluorescence
of the cleavage product was measured using a Luminescence
Spectrometer LS50 (Perkin–Elmer, Fremont, CA, USA).
Annexin-V staining
The percentage of cells undergoing programmed cell death was
measured by double staining with fluorescein-conjugated Annexin-
V and 40,6-diamidinophenylindole. Cells were washed and exposed
to a solution containing 20 ml of Annexin-V-Fluos (Roche
Diagnostic Systems, Mannheim, Germany) according to the
manufacturer’s protocol. The cells were then washed and exposed
to 40,6-diamidinophenylindole (1 mg/ml) (Roche Diagnostic Sys-
tems, Mannheim, Germany) for 15 min at 371C. The percentage of
Annexin (þ ) cells were determined with a fluorescence microscope
(Axioscope; Zeiss, Jena, Germany).
Cell viability assay
The cell viability kit (CCK-8, Dojindo Molecular Technologies Inc.,
Gaithersburg, MD, USA) was used according to the manufacturer’s
protocol. Z-VAD-fmk was obtained from Calbiochem (Darmstadt,
Germany).
Statistical analysis
Each experiment has been repeated three times. Means and s.d. have
been calculated for all the independent experiments. In each
experiment, differences in means were tested for significance using
the Student’s t-test.
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